Orthofix’s Q1 Loss of $20.9M on $196.7M Revenue; Spine Fixation Up 6%
Orthofix reported Q1 net loss of $20.9 million (52 cents per share) on $196.7 million revenue, with adjusted EPS loss of 12 cents. Spine Fixation grew 6% on 7D FLASH navigation, top 30 distributors delivered 27% growth and full-year revenue guides $850–860 million with H2 growth ramp to 6%.
1. Q1 Financial Results
Orthofix posted a net loss of $20.9 million in Q1 2026 on revenue of $196.7 million, translating to a GAAP loss of 52 cents per share and an adjusted EPS loss of 12 cents after excluding non-recurring costs and stock option expenses.
2. Segment Performance and Operational Highlights
Therapeutic Solutions continued to outperform, contributing to margin expansion and cash generation. Spine Fixation revenue rose 6% supported by deeper procedural penetration and the 7D FLASH navigation system, while Biologics improved sequentially via expanded account penetration. Distributor transition efforts were completed, with the top 30 partners delivering 27% year-over-year growth.
3. Strategic Initiatives and Product Launches
In April, management simplified the spine leadership structure to accelerate decision-making and accountability as the company shifts from restructuring to execution. Orthofix plans a full market launch of the VIRATA open system and an alpha launch of VIRATA MIS in the second half of 2026 to bolster its spine portfolio.
4. Full-Year 2026 Guidance
Orthofix maintains full-year revenue guidance of $850 million to $860 million, projecting growth acceleration from 5% in H1 to 6% in H2. Limb Reconstruction is expected to return to double-digit U.S. growth in H2 as capital sales pipelines strengthen, and durable biologics growth will be driven by clinical evidence and physician advocacy by year-end.